Stock Screener App

무료 - Play StoreApp Store

설치하다 설치하다

MDCX

$1.932.66%0.05

프리마켓: 1.74-0.19 -9.84%

Medicus Pharma Ltd (MDCX)

Date: O: H: L: C: Vol:

Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스

Medicus Pharma Ltd. Warrant (MDCXW) Jumps 22.22% to $0.33, Testing $0.35 Resistance - Total Put Call - https://www.siam.in/

Ten straight business days of $1-or-higher share bids restored Medicus Pharma's Nasdaq compliance. - Stock Titan

Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire

Medicus Pharma regains Nasdaq compliance with minimum bid price rule - Investing.com

Form PRE 14A MEDICUS PHARMA LTD. For: 19 October By Investing.com - Investing.com South Africa

Form PRE 14A MEDICUS PHARMA LTD. For: 19 October By Investing.com - Investing.com Australia

Form PRE 14A MEDICUS PHARMA LTD. For: 19 October By Investing.com - Investing.com UK

Medicus Pharma Announces Nasdaq-Compliant Share Consolidation - The Globe and Mail

409,411 directly owned shares are only part of an amended Medicus Pharma (MDCX) stake report. - Stock Titan

Medicus Pharma Warrant (MDCXW) Jumps 66.67% to $0.20 as Buyers Probe Upper Range - Put Flow Alert - https://www.dars.gov.et/

The FDA authorized a planned skin-cancer study for people with a rare inherited condition. - Stock Titan

Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why - Benzinga

Medicus Pharma to implement 50-for-1 share consolidation to meet Nasdaq minimum bid - TradingView

Medicus Pharma to execute 50-to-1 reverse stock split on Oct. 12 - StreetInsider

Medicus Pharma Ltd. Warrant (MDCXW) Holds Flat at $0.35 Inside a Narrow Trading Band - MACD Signal Stocks - https://www.dars.gov.et/

Medicus Pharma Warrant (MDCXW) Trades Flat at $0.35, Pinned Between $0.33 Support and $0.37 Resistance - Profit Surge Picks - https://www.siam.in/

Medicus Pharma Ltd. (MDCX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Dr. Raza Bokhari Discloses Investment at Medicus Pharma Ltd. with 5.3% Stake - TradingView

Medicus Pharma ends standby equity purchase agreement with Yorkville - Investing.com

How big is Medicus Pharma (MDCX) CEO Raza Bokhari's stake? - Stock Titan

MDCX 8-K Filings - Medicus Pharma Ltd. SEC 8-K - Stock Titan

FDA Clears Medicus SkinJect Study for Gorlin Syndrome - MyChesCo

Inside the deal: How a Montco biotech secured a Pfizer drug candidate - The Business Journals

Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com Nigeria

Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com Nigeria

Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com India

Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com

Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com India

Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com UK

Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com

Medicus Pharma posts phase 2 study results for skin cancer drug By Investing.com - Investing.com Australia

Medicus Pharma officers receive restricted shares in lieu of cash bonuses By Investing.com - Investing.com South Africa

Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Nigeria

Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news

Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Yahoo Finance

Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance

Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz

Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com India

Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Canada

Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan - Quiver Quantitative

Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com UK

FDA authorizes the next study of a skin cancer patch - Stock Titan

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz

Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news

Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan

Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - stocktitan.net

Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - stocktitan.net

Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan

CFO adds Medicus Pharma (MDCX) stock and options - stocktitan.net

Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance

MDCX와(과) 유사한 종목

MIRA$0.53722.06%

AMRN$12.130.17%